Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
about
Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trialMechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty ratsEffects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.Acute Hepatic Insulin Resistance Contributes to Hyperglycemia in Rats Following Myocardial Infarction.Protective effects of PPARγ agonist in acute nephrotic syndrome.Can the electrophysiological action of rosiglitazone explain its cardiac side effects?Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesityPioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectivesGenomic profiling in nuclear receptor-mediated toxicity.Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J miceThiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeysCardiovascular risk of rosiglitazone: another perspective.Factors associated with weight loss after gastric bypass.Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome.Review article: Thiazolidinediones and heart failure.Thiazolidinediones and cardiovascular risk - a question of balance.Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors.Insulin-sensitizing effects of a novel alpha-methyl- alpha -phenoxylpropionate derivative in vitro.Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster.The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.Insulin resistance and impaired baroreflex gain during pregnancy.Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidences for beneficial effect of pioglitazone.Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes.
P2860
Q28469197-EBC5DF17-2DF2-431D-91B0-FD2FCEB92EC4Q28567397-D9E642DD-0E6C-4986-B347-CAF4D97854E9Q35073600-18DF29A6-0D32-40FE-B824-0F7396427EC7Q35707124-66482031-CC08-4C98-B024-D3EC1D795215Q35747241-15755867-EEBF-431E-9080-77C2CA1C1151Q36032128-29D607E1-BBE7-4530-B44B-582F218EA8E4Q36296839-E7ABB520-7CEC-4B15-8332-68D209D8FCD9Q36407383-061CFF25-3F98-4F63-937F-D7155088D2ACQ36512559-FF6660F4-046F-4DC1-90CF-B60EE1C49552Q36569766-FE046D4C-2055-45DD-9B36-11EE65FD8B1EQ36812788-01AAFBDF-B6E7-4F64-A117-B6376FA070D2Q36846922-63BEFF3C-85D1-4EC6-B2DD-A38DC0865598Q36909303-184B7DC3-8370-411B-91A6-C8E2C6D5FD51Q36972748-AAF8AC57-4C9F-4AD1-A916-CB281D0ACFB1Q37146413-3B1D0FA4-3E5D-4C10-A414-3B894AC92E25Q37192464-AB621B16-0F95-4255-BCEA-30DF04E07F23Q37250408-001EAB65-49DC-40A0-82E0-D24D642265D3Q37322689-C652080A-6B42-4B9D-BD15-A29BFC11C8B9Q37355685-0F97547E-8FBE-4B57-8133-89D7DD7C97FFQ37586657-23CD6633-CCC0-470F-B5BB-2B8A05588B34Q37724501-19CEF6E4-D576-4027-AF2F-DE46AD66DF24Q37777027-1C295D54-F772-41D7-B0F1-0C31D2AFDD04Q37992593-5E373B1B-5D77-4B43-97EB-E0BCD9DAF1F4Q38320716-B9DAA2CB-259C-41CA-BBC5-5A306965271EQ40170737-98E48CB7-A8B2-4845-8880-4AE3002E3716Q42936496-F85A2831-36AE-46E0-9C66-9259E25B1467Q44582287-B43776AA-9E49-49D8-AB0B-726DC9B22F4DQ47307305-C02043AA-90AF-4112-AE24-45EB6340721CQ48271249-164617AB-6A70-41B6-B5F9-E8F32A8AEC4FQ51285766-01B1054D-DDA7-45F1-8B30-FAE41C03A763Q51390042-2606871C-0F28-484B-823A-3C7476D1BA8DQ52978235-B4274BC1-7FA7-4D51-8C52-0576A0255853
P2860
Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Thiazolidinediones: a review o ...... al efficacy, and tolerability.
@ast
Thiazolidinediones: a review o ...... al efficacy, and tolerability.
@en
type
label
Thiazolidinediones: a review o ...... al efficacy, and tolerability.
@ast
Thiazolidinediones: a review o ...... al efficacy, and tolerability.
@en
prefLabel
Thiazolidinediones: a review o ...... al efficacy, and tolerability.
@ast
Thiazolidinediones: a review o ...... al efficacy, and tolerability.
@en
P356
P1476
Thiazolidinediones: a review o ...... al efficacy, and tolerability.
@en
P2093
Abu R Vasudevan
Ashok Balasubramanyam
P304
P356
10.1089/DIA.2004.6.850
P577
2004-12-01T00:00:00Z